8 completed, 1 not yet recruiting, 1 recruiting, 1 terminated. 12 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 8, Not yet recruiting 1, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 3 | 2 | Recruiting 1, Terminated 1 |
| Phase 1 | 1 | Unknown 1 |
Follow Chikungunya Fever: new trials by email Literature Review of Chikungunya Fever trials Research Report on Chikungunya Fever
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of IXCHIQ® Vaccine Immunogenicity IXCHIQ vaccine - Healthy Adult, Healthy Adolescents | Phase 2 | Not yet recruiting | Mauro Martins Teixeira | 75 | 2026-09-24 | 2026-09-29 |
| A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age. BBV87 Chikungunya vaccine, Placebo - Active Immunisation for Chikungunya Virus Infection | Phase 2 / Phase 3 | Recruiting | Bharat Biotech International Limited | 1000 | 2026-04-20 | 2026-04-29 |
| A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years VLA1553 full dose, VLA1553 half dose, Control - Chikungunya Virus Infection | Phase 2 | Completed | Valneva Austria GmbH | 304 | 2023-12-18 | 2026-08-13 |
| Seamless Controlled Trial To Evaluate Safety And Immunogenicity of Chikungunya Vaccine in LatinAmerica and Asia BBV87 Chikungunya vaccine, Normal Saline - Chikungunya | Phase 2 / Phase 3 | Terminated | International Vaccine Institute | 3210 | 2021-08-01 | 2025-06-22 |
| Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317) Chikungunya - Chikungunya | Phase 2 | Completed | Bavarian Nordic | 60 | 2019-11-20 | 2024-10-16 |
| Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006) V184, Placebo - Chikungunya Virus Infection | Phase 2 | Completed | Themis Bioscience GmbH | 41 | 2019-07-16 | 2022-09-08 |
| Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005) MV-CHIK lyophilised formulation, low dose, MV-CHIK liquid frozen formulation, low dose, MV-CHIK SPS® formulation, low dose - Chikungunya Virus Infection | Phase 2 | Completed | Themis Bioscience GmbH | 60 | 2018-08-22 | 2021-10-22 |
| Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults CHIKV VLP/unadjuvanted, CHIKV VLP/adjuvanted, Placebo - Chikungunya Virus Infection | Phase 2 | Completed | Bavarian Nordic | 445 | 2018-04-18 | 2023-07-03 |
| Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area MV-CHIK, MMR-vaccine - Chikungunya | Phase 2 | Completed | Themis Bioscience GmbH | 34 | 2017-08-09 | 2021-07-19 |
| Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine MV-CHIK low dose, MV-CHIK high dose, Priorix® - Chikungunya Virus Infection | Phase 2 | Completed | Themis Bioscience GmbH | 263 | 2016-08-17 | 2021-10-29 |
| Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults VRC-CHKVLP059-00-VP, VRC-PBSPLA043-00-VP - Chikungunya Virus Infection | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 400 | 2015-11-18 | 2020-10-22 |
| Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins anti-CHIKV hyperimmune immunoglobulins - Chikungunya Virus Infection | Phase 1 / Phase 2 | Unknown | Centre Hospitalier Universitaire de la Guadeloupe | 40 | 2014-09-01 | 2014-11-03 |
Alphavirus Infections (12) · Arbovirus Infections (12) · Infections (12) · Mosquito-Borne Diseases (12) · RNA Virus Infections (12) · Togaviridae Infections (12) · Vector Borne Diseases (12) · Virus Diseases (12) · Disease Attributes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Measles-Mumps-Rubella Vaccine (2) · Dosage Forms (1) · Saline Solution (1) · Sodium Chloride (1)
Themis Bioscience GmbH (4) · Bavarian Nordic (2) · Bharat Biotech International Limited (1) · Centre Hospitalier Universitaire de la Guadeloupe (1) · International Vaccine Institute (1) · Mauro Martins Teixeira (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Valneva Austria GmbH (1)
Puerto Rico (3) · Dominican Republic (2) · United States (2) · Austria (1) · Brazil (1) · Colombia (1) · Costa Rica (1) · France (1) · Germany (1) · Guadeloupe (1) · Guatemala (1) · Haiti (1) · Honduras (1) · India (1) · Martinique (1)
Clemente Diaz, MD (2) · James McCarty, MD (2) · Andre Cabie, MD (1) · Bruno Hoen, MD (1) · Grace Chen, MD (1) · Jean W Pape, MD (1) · Julie Ledgerwood, DO (1) · Mauro M Teixeira, MD, Phd (1) · Nicolas Rosario, MD (1) · Sushant Sahastrabuddhe, MBBS, MPH (1) · Yeycy Donastorg, MD (1)
PMID 25739878, PMID 30409443, PMID 32286643, PMID 34582377, PMID 35709798, PMID 37690874, PMID 39954701, PMID 41652122
2014 (1), 2015 (1), 2018 (1)